Pemgarda
NCCN Guidelines Recommend mAbs for COVID-19 PrEP in People With Cancer
NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections advise clinicians recommend mAbs to ...
AUGUST 4, 2025
Long Half-Life Seen With Novel mAb for COVID-19
The half life of the novel mAb candidate, VYD2311, may be six months or more.
JULY 8, 2025
Pemgarda Neutralizing Activity Remains Stable Against Current Dominant SARS-CoV-2 Strain
Pemivibart, a next-generation COVID-19 monoclonal antibody (mAb), is still showing clinically meaningful in vitro ...
MARCH 7, 2025
Load more